OLANZAPINE ODT 5 MG
OLANZAPINE : 5 MG · DIN 02352974 · SANIS HEALTH INC
Health Canada status: MARKETED
What is OLANZAPINE ODT?
OLANZAPINE ODT 5 MG contains OLANZAPINE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02352974, held by SANIS HEALTH INC, supplied as TABLET (ORALLY DISINTEGRATING) for ORAL administration. Health Canada currently lists it as marketed, status dated 25-Mar-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OLANZAPINE ODT used for?
SCHIZOPHRENIA AND RELATED DISORDERS: OLANZAPINE ODT (olanzapine) is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders. In controlled clinical trials, olanzapine was found to improve both positive and negative symptoms. BIPOLAR DISORDER: OLANZAPINE ODT (olanzapine) is indicated for the acute treatment of manic or mixed episodes in bipolar I disorder. Olanzapine may be used as monotherapy or co-therapy with agents commonly used in the treatment of acute bipolar disorder (e.g., lithium or divalproex sodium).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02352974 |
|---|---|
| Brand name | OLANZAPINE ODT |
| Generic / active ingredient | OLANZAPINE : 5 MG |
| Manufacturer | SANIS HEALTH INC |
| Strength | 5 MG |
| Dosage form | TABLET (ORALLY DISINTEGRATING) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AH03 OLANZAPINE |
| AHFS class | 28:16.08.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Mar-2022 |
| Original market date | 2011-10-07 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is OLANZAPINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05AH03 OLANZAPINE. 103 of 271 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OLANZAPINE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02281821 |
| APO-OLANZAPINE | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 02281848 |
| APO-OLANZAPINE | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02281791 |
| APO-OLANZAPINE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02333015 |
| APO-OLANZAPINE | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02281805 |
| APO-OLANZAPINE | 7.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02281813 |
| APO-OLANZAPINE ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360624 |
| APO-OLANZAPINE ODT | 15 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360632 |
| APO-OLANZAPINE ODT | 20 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360640 |
| APO-OLANZAPINE ODT | 5 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360616 |
Who else supplies OLANZAPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OLANZAPINE appears in 1801 registered pack listings across 15 markets, published on 13 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.